Sort
82,697 grants matching “vaccine development”
Therapeutic vaccination to augment stringent response-specific T-cell immunity to MTB persisters
$740,856Petros C Karakousis · Johns Hopkins University · R01 · FY2023 · AI
Chikungunya Virus Replication and Pathogenesis
$740,822Terence S. Dermody · University Of Pittsburgh At Pittsburgh · R01 · FY2017 · AI
Project 4: A permanent off-switch for AAV
$740,799Michael R. Farzan · Boston Children'S Hospital · U19 · FY2024 · AI
Defining BCR evolution during immunization
$740,759Leonidas A Stamatatos · Fred Hutchinson Cancer Research Center · R01 · FY2015 · AI
Immunity to Cryptosporidium
$740,740Boris Striepen · University Of Pennsylvania · R01 · FY2024 · AI
Immunity to Cryptosporidium
$740,740Boris Striepen · University Of Pennsylvania · R01 · FY2023 · AI
Immunity to Cryptosporidium
$740,740Boris Striepen · University Of Pennsylvania · R01 · FY2022 · AI
Defining the impact of host factors on the molecular architecture and bacterial physiology of Staphylococcus aureus abscesses
$740,709James E Cassat · Vanderbilt University Medical Center · R01 · FY2023 · AI
The role of enteric pathogens and antimicrobial resistance in driving clinical and nutritional deterioration, and azithromycin's potential effect, among children discharged from hospital in Kenya
$740,701Patricia Pavlinac · University Of Washington · R01 · FY2021 · AI
Core 3 - Immunobiology Core
$740,506Derek Wilson Cain · Duke University · U54 · FY2025 · AI
Broadly Specific Needle-Free Vaccines against Emerging and Biothreat Viruses
$740,494Alexander Bukreyev · University Of Texas Med Br Galveston · R01 · FY2016 · AI
Broadly Specific Needle-Free Vaccines against Emerging and Biothreat Viruses
$740,494Alexander Bukreyev · University Of Texas Med Br Galveston · R01 · FY2017 · AI
Broadly Specific Needle-Free Vaccines against Emerging and Biothreat Viruses
$740,494Alexander Bukreyev · University Of Texas Med Br Galveston · R01 · FY2015 · AI
Preclinical Toxicology: Safety Evaluation of pNGVL4a-CRT-E6E7L2 (detox) Recombinant DNA Vaccine in Mice
$740,476Lalitha Iyer · Sri International · N01 · FY2014 · CA
Development of a novel vaccine platform: Surface Antigen/Adjuvant Vaccine Engineering (SAAVE)
$740,465Michael Stephen Trent · University Of Georgia · R01 · FY2021 · AI
Enhancing protective antibody responses for a DNA/MVA HIV vaccine
$740,456Harriet L Robinson · Geovax, Inc. · R44 · FY2016 · AI
Elucidating the functions of red blood cell factors in malaria parasite invasion
$740,435Elizabeth S. Egan · Stanford University · R01 · FY2024 · HL
VIOLIN 2.0: Vaccine Information and Ontology LInked kNowledgebase
$740,422Yongqun He · University Of Michigan At Ann Arbor · U24 · FY2024 · AI
Development of 2C inhibitors as broad-spectrum enterovirus antivirals
$740,419Jun Wang · Rutgers Biomedical And Health Sciences · R01 · FY2025 · AI
Enviromental Factors in the Etiology of Autism
$740,417University Of California Davis · P01 · FY2001 · ES
Flipped Germinal Centers
$740,268Duane R. Wesemann · Brigham And Women'S Hospital · R01 · FY2024 · AI
Flipped Germinal Centers
$740,268Duane R. Wesemann · Brigham And Women'S Hospital · R01 · FY2022 · AI
Flipped Germinal Centers
$740,268Duane R. Wesemann · Brigham And Women'S Hospital · R01 · FY2023 · AI
Flipped Germinal Centers
$740,268Duane R. Wesemann · Brigham And Women'S Hospital · R01 · FY2025 · AI
Flipped Germinal Centers
$740,268Duane R. Wesemann · Brigham And Women'S Hospital · R01 · FY2021 · AI